Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of TheraT Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients With HPV 16+ Confirmed Cancers

Next Previous
Trial Profile

A Phase I/II Study of TheraT Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients With HPV 16+ Confirmed Cancers

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HB 201 (Primary) ; HB 201 (Primary) ; HB 202 (Primary) ; Pembrolizumab (Primary)
  • Indications Anal cancer; Cancer; Cervical cancer; Gynaecological cancer; Head and neck cancer; Oropharyngeal cancer; Penile cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Hookipa Pharma

Most Recent Events

  • 14 Nov 2024 According to a HOOKIPA Pharma media release,Enrollment completed in the Phase 2 H200-001 study
  • 14 Nov 2024 Status changed from recruiting to active, no longer recruiting.
  • 04 Jun 2024 Updated results assessing HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top